Reversing deleterious protein aggregation with re-engineered protein disaggregases

Cell Cycle

Volumn 13, Issue 9, 2014, Pages 1379-1383

  Jackrel, MeredithE ^a   Shorter, James ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Amyloid; Disaggregation; Hsp104; Neurodegeneration; Protein misfolding disorders; Proteostasis

Indexed keywords

ALPHA SYNUCLEIN; CHAPERONE; FUSED IN SARCOMA PROTEIN; HEAT SHOCK PROTEIN 104; PRION PROTEIN; PROTEIN VARIANT; TAR DNA BINDING PROTEIN; HEAT SHOCK PROTEIN; HSP104 PROTEIN, S CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; CYTOTOXICITY; DOPAMINERGIC ACTIVITY; HUNTINGTON CHOREA; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN REENGINEERING; REVIEW; UPREGULATION; YEAST; ANIMAL; CAENORHABDITIS ELEGANS; GENETICS; HUMAN; METABOLISM; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEOSTASIS DEFICIENCIES; SACCHAROMYCES CEREVISIAE; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN ENGINEERING; PROTEOSTASIS DEFICIENCIES; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 84899739068     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.28709     Document Type: Review

References (43)

1. Dobson CM. Protein folding and misfolding. Nature 2003; 426:884-90; PMID:14685248; http://dx.doi.org/10.1038/nature02261
2. Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004; 10:1055-63; PMID:15459709; http://dx.doi.org/10.1038/nm1113
3. Morimoto RI. Stress, aging, and neurodegenerative disease. N Engl J Med 2006; 355:2254-5; PMID:17124027; http://dx.doi.org/10.1056/NEJMcibr065573
4. Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 2013; 14:248-64; PMID:23463272; http://dx.doi.org/ 10.1038/nrn3430
5. King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res 2012; 1462:61-80; PMID:22445064; http://dx.doi.org/10.1016/j.brainres.2012.01.016
6. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314:130-3; PMID:17023659; http://dx.doi.org/10.1126/science.1134108
7. Vance C, Rogelj B, Hortobágyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323:1208-11; PMID:19251628; http://dx.doi.org/10.1126/science.1165942
8. Kwiatkowski TJ Jr., Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, et al. Mutations in the FUS/ TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323:1205-8; PMID:19251627; http://dx.doi.org/10.1126/science. 1166066
9. Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci 2010; 123:1191-201; PMID:20356930; http://dx.doi.org/10.1242/jcs.051672
10. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338:949-53; PMID:23161999; http://dx.doi.org/10.1126/science.1227157
11. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, et al. Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 2013; 154:103-17; PMID:23827677; http://dx.doi.org/10.1016/j.cell.2013.05.057
12. Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU. Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem 2013; 82:323-55; PMID:23746257; http://dx.doi.org/10.1146/annurev-biochem-060208-092442
13. Warrick JM, Paulson HL, Gray-Board GL, Bui QT, Fischbeck KH, Pittman RN, Bonini NM. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998; 93:939-49; PMID:9635424; http://dx.doi.org/10.1016/S0092-8674(00)81200-3
14. Cushman-Nick M, Bonini NM, Shorter J. Hsp104 suppresses polyglutamine-induced degeneration post onset in a drosophila MJD/SCA3 model. PLoS Genet 2013; 9:e1003781; PMID:24039611; http://dx.doi.org/10.1371/journal. pgen.1003781
15. Torrente MP, Shorter J. The metazoan protein disaggregase and amyloid depolymerase system: Hsp110, Hsp70, Hsp40, and small heat shock proteins. Prion 2014; 7; PMID:24401655
16. Duennwald ML, Echeverria A, Shorter J. Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans. PLoS Biol 2012; 10:e1001346; PMID:22723742; http://dx.doi.org/10.1371/journal. pbio.1001346
17. Shorter J. The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system. PLoS One 2011; 6:e26319; PMID:22022600; http://dx.doi.org/10. 1371/journal.pone.0026319
18. Rampelt H, Kirstein-Miles J, Nillegoda NB, Chi K, Scholz SR, Morimoto RI, Bukau B. Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J 2012; 31:4221-35; PMID:22990239; http://dx.doi.org/10.1038/emboj.2012.264
19. Mattoo RU, Sharma SK, Priya S, Finka A, Goloubinoff P. Hsp110 is a bona fide chaperone using ATP to unfold stable misfolded polypeptides and reciprocally collaborate with Hsp70 to solubilize protein aggregates. J Biol Chem 2013; 288:21399-411; PMID:23737532; http://dx.doi.org/10.1074/jbc.M113. 479253
20. Shorter J. Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals 2008; 16:63-74; PMID:18097161; http://dx.doi.org/10. 1159/000109760
21. Glover JR, Lindquist S. Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. Cell 1998; 94:73-82; PMID:9674429; http://dx.doi.org/10.1016/S0092-8674(00)81223-4
22. Vashist S, Cushman M, Shorter J. Applying Hsp104 to protein-misfolding disorders. Biochem Cell Biol 2010; 88:1-13; PMID:20130674; http://dx.doi.org/10. 1139/O09-121
23. DeSantis ME, Leung EH, Sweeny EA, Jackrel ME, Cushman-Nick M, Neuhaus-Follini A, Vashist S, Sochor MA, Knight MN, Shorter J. Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell 2012; 151:778-93; PMID:23141537; http://dx.doi.org/10.1016/j.cell. 2012.09.038
24. Lo Bianco C, Shorter J, Régulier E, Lashuel H, Iwatsubo T, Lindquist S, Aebischer P. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 2008; 118:3087-97; PMID:18704197; http://dx.doi.org/10.1172/JCI35781
25. Sweeny EA, Shorter J. Prion proteostasis: Hsp104 meets its supporting cast. Prion 2008; 2:135-40; PMID:19242125; http://dx.doi.org/10.4161/pri.2.4. 7952
26. Jackrel ME, DeSantis ME, Martinez BA, Castellano LM, Stewart RM, Caldwell KA, Caldwell GA, Shorter J. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell 2014; 156:170-82; PMID:24439375; http://dx.doi.org/10.1016/j.cell.2013.11.047
27. Vacher C, Garcia-Oroz L, Rubinsztein DC. Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. Hum Mol Genet 2005; 14:3425-33; PMID:16204350; http://dx.doi.org/10.1093/hmg/ddi372
28. Warrick JM, Chan HYE, Gray-Board GL, Chai Y, Paulson HL, Bonini NM. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 1999; 23:425-8; PMID:10581028; http://dx.doi.org/10.1038/70532
29. Kuo Y, Ren S, Lao U, Edgar BA, Wang T. Suppression of polyglutamine protein toxicity by co-expression of a heat-shock protein 40 and a heat-shock protein 110. Cell Death Dis 2013; 4:e833; PMID:24091676; http://dx.doi.org/10. 1038/cddis.2013.351
30. DeSantis ME, Shorter J. The elusive middle domain of Hsp104 and ClpB: location and function. Biochim Biophys Acta 2012; 1823:29-39; PMID:21843558; http://dx.doi.org/10.1016/j.bbamcr.2011.07.014
31. Tessarz P, Mogk A, Bukau B. Substrate threading through the central pore of the Hsp104 chaperone as a common mechanism for protein disaggregation and prion propagation. Mol Microbiol 2008; 68:87-97; PMID:18312264; http://dx.doi.org/10.1111/j.1365-2958.2008.06135.x
32. Saibil H. Chaperone machines for protein folding, unfolding and disaggregation. Nat Rev Mol Cell Biol 2013; 14:630-42; PMID:24026055; http://dx.doi.org/10.1038/nrm3658
33. Gitler AD. Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease? Neurosignals 2008; 16:52-62; PMID:18097160; http://dx.doi.org/10.1159/000109759
34. Khurana V, Lindquist S. Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast? Nat Rev Neurosci 2010; 11:436-49; PMID:20424620; http://dx.doi.org/10.1038/nrn2809
35. Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A 2008; 105:6439-44; PMID:18434538; http://dx.doi.org/10.1073/pnas.0802082105
36. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, Gitler AD. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol 2011; 9:e1000614; PMID:21541367; http://dx.doi.org/10.1371/journal.pbio.1000614
37. Ju S, Tardiff DF, Han H, Divya K, Zhong Q, Maquat LE, Bosco DA, Hayward LJ, Brown RH Jr., Lindquist S, et al. A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol 2011; 9:e1001052; PMID:21541368; http://dx.doi.org/10. 1371/journal.pbio.1001052
38. Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 2003; 302:1772-5; PMID:14657500; http://dx.doi.org/10.1126/science.1090439
39. Elden AC, Kim H-J, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010; 466:1069-75; PMID:20740007; http://dx.doi.org/10.1038/nature09320
40. Tardiff DF, Jui NT, Khurana V, Tambe MA, Thompson ML, Chung CY, Kamadurai HB, Kim HT, Lancaster AK, Caldwell KA, et al. Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates á -synuclein toxicity in neurons. Science 2013; 342:979-83; PMID:24158909; http://dx.doi.org/10.1126/science.1245321
41. Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, et al. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science 2013; 342:983-7; PMID:24158904; http://dx.doi.org/10.1126/science.1245296
42. Berkowitz LA, Hamamichi S, Knight AL, Harrington AJ, Caldwell GA, Caldwell KA. Application of a C. elegans dopamine neuron degeneration assay for the validation of potential Parkinson's disease genes. J Vis Exp 2008:e835; PMID:19066512
43. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, et al. α-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006; 313:324-8; PMID:16794039; http://dx.doi.org/10.1126/science.1129462